Undifferentiated connective tissue disease (UCTD): what the label means and what to expect

The immune system normally makes antibodies that attack germs. In autoimmune disease it produces antibodies against the body's own tissues, causing inflammation. The West Suffolk NHS Foundation Trust leaflet explains that connective tissue diseases are autoimmune diseases in which the body makes antibodies against its own connective tissue, the structural tissue that holds cells together. These include lupus, rheumatoid arthritis, scleroderma (systemic sclerosis), polymyositis and dermatomyositis.

Each of those diseases has typical clinical findings and blood test patterns, but each can start with very mild symptoms before the classic features develop. When the classic features are not yet present, doctors often refer to the condition as undifferentiated connective tissue disease, or UCTD for short.

Specialist rheumatology services list UCTD alongside conditions such as systemic lupus erythematosus, antiphospholipid syndrome, systemic sclerosis, Sjögren's syndrome, inflammatory myopathies, vasculitis, mixed connective tissue disease and Behçet's disease within the group of connective tissue diseases. The Royal United Hospitals Bath rheumatology service and the Cornwall NHS referral guide both set it out in this way.

The leaflet says that the symptoms vary greatly from one individual to another. They include some or all of joint pain, joint swelling, skin rashes, kidney disease, breathing problems, heartburn or swallowing problems, mouth ulcers, skin tightening and thickening, and Raynaud's phenomenon (fingers and toes changing colour on exposure to cold).

Your own pattern of symptoms will determine which tests and monitoring are needed. The Cornwall guide lists features that prompt a referral, including inflammatory arthritis, a photosensitive rash, recurrent mouth ulcers, unexplained pleurisy or pericarditis, scarring alopecia and unexplained blood or urine abnormalities.

There is no single test. The leaflet explains that diagnosis is based on history, examination findings and blood tests. The Cornwall guide lists investigations that are usually done before referral: urine testing and blood pressure, blood counts, kidney and liver tests, bone profile and CRP, ANA if lupus, Sjögren's or systemic sclerosis is suspected, complement if lupus is suspected, CK if myositis is suspected, and a chest X-ray, with ANCA considered if vasculitis is suspected.

The same guide gives an important caution. People with a weakly positive ANA (1:80) and no other symptoms or signs, or with non-specific widespread musculoskeletal pain and a weakly positive ANA, should not routinely be referred, because positive ANA has been reported in up to 20 to 30% of healthy individuals. Equally, many people with systemic autoimmune disease need specialist referral regardless of antibody results. A rheumatologist interprets the whole picture.

The leaflet says treatment is based on which features are causing symptoms, and the outlook varies accordingly. Treatment is often directed at damping down inflammation using anti-inflammatory and immunosuppressant medicines, including non-steroidal anti-inflammatory drugs (NSAIDs), steroids such as prednisolone, antimalarial drugs such as hydroxychloroquine, and sometimes other immune-suppressing drugs such as methotrexate, azathioprine, cyclophosphamide and TNF inhibitors.

It also mentions physiotherapy for certain joints, treatment of high blood pressure when needed to protect the kidneys, and measures for heartburn such as raising the head of the bed and medicines like omeprazole or lansoprazole. For Raynaud's phenomenon, it recommends hand and body-warming techniques while protecting the fingers from injury, and tablets such as nifedipine or losartan, or nitroglycerin cream, can be used to open up the blood vessels.

Many people with mild symptoms need only simple measures and monitoring. Not every medicine used is licensed specifically for UCTD, so ask your rheumatology team to explain the benefits and risks of each option.

The leaflet says the outlook very much depends on the location and intensity of the organs affected, and that those who are treated and monitored early tend to have better outcomes. It also says people with UCTD may never develop a fully definable condition, or may eventually develop a classic connective tissue disease, usually within five years of diagnosis.

Monitoring commonly involves periodic review with symptom questions, blood and urine tests, and checks of blood pressure. If your rheumatologist is concerned about the lungs they may arrange breathing tests or an echocardiogram, as the leaflet describes for mixed connective tissue disease. Tell your team promptly about new symptoms such as persistent breathlessness, a new rash, swollen joints or foamy urine.

The leaflet notes that there is no prevention for these conditions, so the aim is early recognition and sensible treatment rather than avoidance.

Receiving a diagnosis that is described as undifferentiated can be unsettling, because it says what you do not have rather than what you do. It can help to ask your rheumatologist what features they are watching for, how often you will be seen, and which symptoms should prompt an earlier appointment.

General measures such as protecting the skin from strong sun if you have a photosensitive rash, keeping warm with Raynaud's, staying active within your limits and pacing activities during fatigue are commonly advised. If low mood or anxiety are significant, tell your GP or team, as support is available.